The HemOnc Pulse
Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Chadi Nabhan, MD, MBA, FACP, covering all topics in the world of hematologic oncology.
Advertisement
Advertisement
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
"MRD positivity is an indication to go to transplant in these patients,” Dr. Radich said.
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
The debate on the future of Bruton's tyrosine kinase (BTK) inhibitors in CLL.
Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.
We saw patients [who] were going to die, and it saved their life and then it's gone and it's shocking," she explained.
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Dr. Fonseca offers his thoughts on the future of multiple myeloma treatment and more.
Jonathan Friedberg, MD, MMSc, discusses the trial and its implications for the field.
Dr. Garcia-Manero discusses key data from the phase III COMMANDS trial.
Dr. Shadman rounds up the latest news on CLL from the summer conferences in this episode of The HemOnc Pulse.
The changes brought about by molecular characterization have a profound impact on real-world clinical care for AML.
Nitin Jain, MD, discusses the data on venetoclax combinations in CLL and key frontline treatment considerations.
Dr. Nowakowski discusses the L-MIND study and the "revolution in the treatment of DLBCL" in recent years.
Naveen Pemmaraju, MD, discusses the rare, ultrarare, and forgotten blood cancers on this episode of The HemOnc Pulse.
Dr. Majhail explores strategies to improve access to CAR-T therapy.
Drs. Vijenthira and Prica discuss their study and why its results differed from a similar study published in late 2022.
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
Updates From Other BCT Partners
Raajit Rampal, MD, PhD, and the "Blood Cancer Talks" hosts discuss the diagnosis and management of essential thrombocythemia.
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
Dr. Tefferi discussed choosing the right mentors, balancing the clinical and the research, and becoming a "master physician."
Dr. Dispenzieri, of the Mayo Clinic, joins the "Blood Cancer Talks" hosts to discuss how to treat and manage AL amyloidosis.
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
